NVS Earnings & Financial Statements
Novartis AG
$146.88
+$4.47(+3.14%)
53
Overall
80
Value
20
Tech
60
Quality
Market Cap
$280.27B
Volume
1.65M
52W Range
$121.57 - $170.46
Target Price
$151.30
NVS earnings and financial statements: Novartis AG's income statement, balance sheet and cash flow statement, annual and quarterly.
NVS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $56.67B | $51.72B | $46.66B | $43.46B | $43.97B |
| Cost of revenue | $13.70B | $12.83B | $12.47B | $11.58B | $11.73B |
| Operating income | $17.63B | $14.51B | $9.69B | $9.20B | $11.69B |
| EBITDA | $17.63B | $14.51B | $9.91B | $14.68B | $30.91B |
| Net income | $13.98B | $11.66B | $15.95B | $6.96B | $24.02B |
| EPS (diluted) | - | $5.87 | $7.10 | $3.17 | $10.63 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $110.95B | $102.25B | $98.34B | $117.45B | $131.79B |
| Total liabilities | $64.40B | $58.12B | $43.20B | $58.03B | $63.97B |
| Shareholders’ equity | $46.13B | $44.05B | $46.67B | $59.34B | $67.66B |
| Cash and equivalents | $11.44B | $11.46B | $13.39B | $2.88B | $3.40B |
| Long-term debt | $29.59B | $22.93B | $20.03B | $21.78B | $24.52B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $19.14B | $17.62B | $14.46B | $14.24B | $15.07B |
| Capital expenditure | - | - | - | $2.67B | -$2.97B |
| Free cash flow | $15.24B | $13.80B | $13.90B | $11.77B | $12.79B |
| Dividends paid | $7.82B | $7.62B | $7.25B | $7.51B | $7.37B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVS | $146.88 | +3.1% | 1.65M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |